Cargando…

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache

BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navratilova, Edita, Behravesh, Sasan, Oyarzo, Janice, Dodick, David W, Banerjee, Pradeep, Porreca, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412872/ https://www.ncbi.nlm.nih.gov/pubmed/32615788 http://dx.doi.org/10.1177/0333102420938652

Ejemplares similares

Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
por: Rau, Jill C, et al.
Publicado: (2020)

Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache
por: Navratilova, Edita, et al.
Publicado: (2022)

Exploring the neurobiology of the premonitory phase of migraine preclinically – a role for hypothalamic kappa opioid receptors?
por: Kopruszinski, Caroline M., et al.
Publicado: (2022)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Correction to: Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Mechanistic Investigations Support Liver Safety of Ubrogepant
por: Smith, Brenda, et al.
Publicado: (2020)

Ubrogepant to Treat Acute Migraine in Adults
por: Edinoff, Amber N., et al.
Publicado: (2021)

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
por: Lipton, Richard B., et al.
Publicado: (2022)

Medication-overuse headache: an update
por: Sarchielli, Paola
Publicado: (2015)

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Medication–overuse headache: pathophysiological insights
por: Calabresi, P., et al.
Publicado: (2005)

Medication-overuse headache: a review
por: Kristoffersen, Espen Saxhaug, et al.
Publicado: (2014)

Preventing and treating medication overuse headache
por: Alstadhaug, Karl B., et al.
Publicado: (2017)

Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline
por: Diener, Hans-Christoph, et al.
Publicado: (2022)

Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain
por: Lançon, Kevin, et al.
Publicado: (2021)

Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
por: Hutchinson, Susan, et al.
Publicado: (2021)

Treatment and outcome in medication overuse headache patients
por: Mitsikostas, D, et al.
Publicado: (2013)

EHMTI-0303. Treatment of medication overuse headache
por: Madsen, SK, et al.
Publicado: (2014)

Cortical and Subcortical Alterations in Medication Overuse Headache
por: Mehnert, Jan, et al.
Publicado: (2018)

Severity of Analgesic Dependence and Medication-overuse Headache
por: Lundqvist, Christofer, et al.
Publicado: (2019)

Medication-overuse headache: causes, consequences and management
por: Massey, Thomas H., et al.
Publicado: (2021)

Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache
por: Gaul, Charly, et al.
Publicado: (2011)

Nasal decongestant and chronic headache: a case of naphazoline overuse headache?
por: Di Lorenzo, Cherubino, et al.
Publicado: (2013)

A CARE pathway in medication–overuse headache: the experience of the Headache Centre in Pavia
por: Sances, G., et al.
Publicado: (2005)

Medication-Overuse Headache: Differences between Daily and Near-Daily Headache Patients
por: Krymchantowski, Abouch V., et al.
Publicado: (2016)

Treatment of withdrawal headache in patients with medication overuse headache: a pilot study
por: Cevoli, Sabina, et al.
Publicado: (2017)

Efficacy of (S)-lacosamide in preclinical models of cephalic pain
por: Moutal, Aubin, et al.
Publicado: (2016)

Prevalence of medication overuse headache in an interdisciplinary pain clinic
por: Schmid, Corinne Wanner, et al.
Publicado: (2013)

EHMTI-0195. Cortical changes in medication-overuse headache
por: Riederer, F, et al.
Publicado: (2014)

Health status after detoxification in medication overuse headache
por: Martelletti, Paolo
Publicado: (2004)

Volume gain of periaqueductal gray in medication-overuse headache
por: Chen, Zhiye, et al.
Publicado: (2017)

Volumetric abnormalities of thalamic subnuclei in medication-overuse headache
por: Chen, Zhiye, et al.
Publicado: (2017)

Medication-overuse headache: clinical profile and management strategies
por: AlQuliti, Khalid W., et al.
Publicado: (2023)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Medication Overuse Withdrawal in Children and Adolescents Does Not Always Improve Headache: A Cross-Sectional Study
por: Moavero, Romina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tl88c4sjj2k1g00kot17lbmngj